ANNONCE
ANNONCE
ANNONCE

Ameloblastomer, incidens og behandling

ABSTRACT

Sekundær artikel Dato: 28.05.2015

Formål – Formålet med undersøgelsen var at beskrive incidensen af ameloblastomer i Norge i perioden 2000- 2009 og at evaluere kirurgiske behandlingsmetoder i relation til tumorrecidiv. Materiale og metoder – Information vedrørende patienter, som var behandlet for ameloblastomer i Norge blev indhentet fra alle laboratorier som udfører oralpatologiske undersøgelser. Vi samlede desuden information angående kirurgisk behandling og behandlingsresultater for alle patienter, der var blevet behandlet for ameloblastomer på Haukeland universitetssygehus (HUS). Resultater – 95 patienter var registreret med diagnosen ameloblastom i Norge i 10-årsperioden. 81 patienter var diagnostiseret med primærtumor, svarende til en incidens af ameloblastomer på 1,6 tilfælde pr. million pr. år. 19 patienter blev behandlet for ameloblastomer på HUS i samme periode. 17 af disse blev behandlet konservativt med curettage, og 4 af dem udviklede tumorrecidiv. To patienter blev initialt behandlet med resektion. Konklusioner – Vi finder en incidensrate på 1,6 tilfælde pr. million pr. år i Norge i perioden 2000- 2009. Kirurgisk resektion er associeret med en lav recidivtendens, men behandlingen kan involvere betydeligt tab af knogle og blødtvæv. Curettage kan foretages i udvalgte tilfælde.

Ameloblastomas in Norway: Incidence and treatment modalities Objective – The aim of the present study was to describe the incidence of ameloblastoma in Norway in the period 2000- 2009 and to evaluate surgical treatment modalities in relation to recurrence of the tumour. Study Design – Information regarding patients treated for ameloblastoma in Norway in the ten year period was collected from all laboratories dealing with diagnostic pathology in Norway. For all patients treated at Haukeland University Hospita,l Bergen, we collected information regarding surgical treatment and treatment results. Results – 95 patients were registered with ameloblastoma. Eighty-one patients were diagnosed with primary tumour, corresponding to an incidence of ameloblastoma of 1.6 cases per million per year. 19 patients were treated for ameloblastoma at HUH. Seventeen patients were treated conservatively with curettage and 4 of them experienced tumour recurrence. Two patients were initially treated with resection. Neither of these experienced tumor recurrence. Conclusions – We find an incidence rate of 1.6 cases per million per year in Norway in the period 2000-2009. Surgical resection is associated with a low recurrence rate, but the treatment may involve severe loss of bone and soft tissue. Curettage may be the preferred treatment in selected cases.